

Continuing Education Request Form

Revisiting Pain Management in Cancer Patients: Breakthrough Pain and Its Treatment

To receive continuing credit:

1. Print your name and address to which you would like to have your certificate mailed in the space provided below
2. Complete the program evaluation and post activity test.
3. Mail or fax the completed Program Evaluation Form and this continuing education form to:

Educational Review Systems
3015 Shannon Lakes North, Suite 303
Tallahassee, FL 32309
Phone – 850-906-0779
Fax – 678-401-0258

A test score of 70% or better is required in order to obtain continuing education credit. If you do not achieve a minimum score of 70%, you will be notified by mail and be returned to you at that time. Your answer form may be resubmitted only once, with corrected answers indicated in different color ink. Please allow 4 weeks for certificate processing

Evaluation Questions: Circle one response for each question	Scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent														
1.) Overall program rating	1	2	3	4	5										
2.) Relevance of program to your practice	1	2	3	4	5										
3.) Effectiveness of teaching strategy	1	2	3	4	5										
4.) The educational level of this activity was...	Too Basic		Appropriate	Too Complex											
5.) The presentation was objective, balanced and free of commercial bias?	Yes			No											
6.) The faculty disclosed verbally or in writing significant relationships with commercial supporters	Yes			No											
Faculty Evaluation:	<i>S. Agarwala, MD</i>		<i>K. Hahn, PharmD</i>		<i>B. Nicholson, MD</i>										
1.) Presentation Style	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5
2.) Organization/Clarity	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5
3.) Expertise	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5
4.) Relevance to Objectives	1	2	3	4	5	1	2	3	4	5	1	2	3	4	5
Learning Objectives Review: At the conclusion of the program, participants will be able to:	Was each learning objective met?														
Describe the pathophysiology and characteristics of breakthrough Pain, its prevalence and the negative impact on patients						Yes					No				
Discuss the pharmacokinetics of opioids used to treat cancer pain and characteristics of ideal breakthrough pain treatments						Yes					No				
Evaluate new options for treating breakthrough pain, including investigational agents						Yes					No				
Assess pharmacoeconomic considerations when treating patients with breakthrough pain						Yes					No				
Identify ways to improve collaboration with oncologists to optimize patient care															
Based on information you gained in this activity, do you plan to make any changes in your patient care activity?	Yes			No			NA								
If yes, what changes															

POST-TEST (please circle the one best answer for each question)

1. Investigational rapid onset opioids for breakthrough pain in cancer patients include which of the following?
 - a. Fentanyl buccal soluble film (FBSF)
 - b. Aerosolized liposome encapsulated fentanyl
 - c. Sublingual fentanyl
 - d. All of the above
2. Which opioid class is most appropriate for treating breakthrough pain in cancer patients?
 - a. Rapid onset
 - b. Short acting
 - c. Long acting
 - d. None of the above
3. Cancer patients with breakthrough pain have which of the following when compared to patients without breakthrough pain?
 - a. Increased responsiveness to opioid therapy
 - b. Lower economic burden
 - c. Pain-related functional impairment
 - d. Less psychological distress
4. Which of the following is generally not a characteristic of breakthrough pain?
 - a. Long duration
 - b. Excruciating severity
 - c. May be precipitated by an event
 - d. May be predictable
5. Which of the following supports the need for collaboration among members of the pain management team?
 - a. Patients are often reluctant to bring up issues of pain with their oncologist as they are concerned that doses of chemotherapy drugs may be reduced
 - b. The pharmacist is often the most accessible healthcare professional
 - c. Medication substitutions may occur if pharmacists do not have detailed patient information including the diagnosis of breakthrough pain and why a rapid onset opioid is the best treatment option
 - d. All of the above
6. Which of the following is true about recent data for FBSF and oral transmucosal fentanyl citrate (OTFC)?
 - a. The C_{max} for FBSF was reported to be 62% higher than the C_{max} for OTFC
 - b. The AUC for FBSF was reported to be 40% lower than the AUC for OTFC
 - c. The C_{max} and AUC for FBSF and OTFC are identical
 - d. All of the above
7. Which of the following is false regarding the economics of breakthrough pain?
 - a. Patients with breakthrough pain have higher direct pain-related costs than those without breakthrough pain
 - b. Patients with breakthrough pain report fewer emergency room visits and outpatient doctor visits than those without breakthrough pain
 - c. Results suggest that the use of rapid onset opioids may decrease the need for emergency room visits, the use of parenteral opioids, and hospital admission
 - d. All of the above

of hours (max 2.0): _____ Signature: _____

Please send my certificate of completion to: **(PRINT CLEARLY & LEGIBLY)**

Full Name (First, Middle Initial, Last)


Credential/Degree

Professional Specialty

Job Position/Title

Name of Practice or Organization (include division)

Mailing Address (Street address, City, State, Zip)



Educational Review Systems, Inc
3015 Shannon Lakes North, Suite 303
Tallahassee, FL 32309

() _____ () _____
Office Phone Fax

Email (**required**)



Pharmacy Credit: Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education.

This program is approved for 2 hours (0.2 CEUs). ACPE # 761-000-09-017-H01-P